雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Efficacy of Intravenous Phenobarbital Treatment for Status Epilepticus Emiko Muramoto 1 , Masahiro Mizobuchi 2 , Yoshihiro Sumi 1 , Kazuya Sako 2 , Atsuko Nihira 2 , Akiko Takeuchi 2 , Hirohiko Nakamura 1 1Department of Neurosurgery, Nakamura Memorial Hospital 2Department of Neurology, Nakamura Memorial Hospital Keyword: phenobarbital , status epilepticus , treatment , efficacy , adverse effect pp.983-987
Published Date 2013/8/1
DOI https://doi.org/10.11477/mf.1416101575
  • Abstract
  • Look Inside
  • Reference

Abstract

 Purpose: Intravenous phenobarbital (IV-PB) therapy was launched in Japan in October 2008. We retrospectively investigated its efficacy and tolerability in patients with status epilepticus.  Methods: Forty-three consecutive patients received IV-PB for status epilepticus between June 2009 and April 2011. Among them, 39 patients had underlying diseases, which included acute diseases in 19 patients and chronic conditions in 20 patients. Although 18 patients had been taking antiepileptic drugs (AEDs) before the occurrence of status epilepticus, the blood AED concentrations in 8 patients was below the therapeutic levels. Before the administration of IV-PB, 39 patients were treated with intravenous benzodiazepine, 17 patients were treated with intravenous phenytoin, and 15 patients with intravenous infusion of lidocaine.  Results: The initial doses of IV-PB ranged from 125 to 1,250 mg (1.9-20.0 mg/kg). Additional doses of IV-PB were required in 12 patients. Seizures were controlled in 35 patients (81%) after IV-PB administration. Cessation of status epilepticus was attained in 24 patients after the initial dose and in 11 patients after additional doses. There were no serious adverse effects, although respiratory suppression was observed in 3 patients and drug eruption was observed in 1 patient.  Conclusion: IV-PB is relatively safe and effective for controlling status epilepticus. If the first dose is not effective, additional doses are required up to the recommended maximum dose. (Received: March 7, 2013, Accepted: April 22, 2013)


Copyright © 2013, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有